Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > They delivered on their follow-ups

<< Previous

Bullboard Posts

Next >>

Comment by juniper88on Dec 09, 2024 10:19am

96 Views

Post# 36352555

RE:RE:RE:RE:They delivered on their follow-ups

Personally, I believe these are good result. In my opinion, POC was met. However, the comitee (and I agree) would like to see further testing at a higher dose to see if better result can be attained before going to a Phase II. To me, these results are intriguing and hopefully they can find a partner to keep this going.

<< Previous

Bullboard Posts

Next >>

Full Circle Lithium goes global with its battery fire-fighter